Rocket One Inc. Common Stock (RKTO) Financials

Rocket One Inc. Common Stock (NASDAQ:RKTO) continues to look like a pre-revenue, cash-burning biotech with no operating revenue over the periods provided. The biggest takeaway from the latest quarter is that the company still has a meaningful cash cushion, but it is spending that cash at a steady pace and remains dependent on external financing.

For Q1 2026, Rocket One reported no revenue and a net loss of $2.7 million, which was slightly better than the prior quarter’s loss of $2.7 million and materially better than the larger losses seen in some earlier periods. Operating expenses were essentially flat sequentially, but still high relative to a company with no sales. Cash on the balance sheet fell to $4.0 million from $7.8 million in Q3 2025 and $11.3 million in Q1 2025.

Cash burn is the key issue. The company used $3.1 million in operating cash during Q1 2026 and ended the quarter with a negative net change in cash of $2.2 million. While financing activities provided $701 thousand from common equity issuance, that was not enough to offset ongoing operating losses. Compared with earlier quarters, the trend suggests management is relying on dilution and periodic capital raises to keep funding operations.

Balance sheet quality has weakened year over year, even though it still appears solvent in the near term. Total assets were $5.6 million and total liabilities were $1.4 million at the end of Q1 2026, leaving shareholders’ equity at $4.2 million. That equity base is much lower than the $11.5 million reported in Q1 2025, reflecting the ongoing losses and share issuance activity.

• Cash and equivalents of $4.0 million still provide some short-term operating runway.
• Total liabilities of $1.4 million remain relatively modest versus assets.
• Q1 2026 operating loss improved slightly versus Q4 2025, with operating expenses nearly flat sequentially.
• Financing activity added $701 thousand, showing the company was able to raise capital during the quarter.
• No revenue was reported, so the company is still entirely dependent on funding rather than commercial sales.
• R&D spending remains significant at $1.5 million, which is typical for a development-stage biotech but also contributes to losses.
• Share count remains elevated, indicating ongoing dilution risk for existing shareholders.
• Operating cash flow was negative $3.1 million in Q1 2026, signaling continued cash burn.
• Cash dropped sharply from $7.8 million in Q3 2025 to $4.0 million in Q1 2026.
• Retained earnings remain deeply negative, underscoring years of accumulated losses.

Looking at the multi-quarter trend, Rocket One has consistently posted net losses between roughly $2 million and $4.1 million per quarter over the last year-plus. Cash also moved lower over time, despite occasional financing inflows. In other words, the company has not yet shown a path to self-funding operations through revenue, so investors should expect continued dilution or additional capital raises unless the business model changes materially.

Bottom line: Rocket One’s latest quarter shows limited improvement in losses, but the core story remains unchanged: no revenue, ongoing cash burn, and dependence on financing. That makes the stock highly speculative and tied to future clinical, commercial, or financing developments rather than current operating performance.